Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab + Pembrolizumab + Paclitaxel + Carboplatin in Locally Advanced TNBC
NCT06637306Phase 1Recruiting
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dupilumab in triple-negative breast cancer (TNBC). Primary endpoint: Incidence of severe immune-related adverse events at 4 months. Started Mar 2025; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06637306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637306.